baber/WOPTO huggingface dataset:
Patent NZ-596117-A (NZ)
Title: Novel anti-inflammatory agents
Inventor: ATTWELL SARAH C
IPC: C07D471/04
Filed: 2010-04-21
Abstract: Disclosed herein is the use of quinazolin-4-one derivatives of formula (II) wherein the substituents are as defined within the specification, in the manufacture of a medicament for inhibiting the expression of IL-6 and/or VCAM-1 in a subject. Also disclosed are specific compounds including: 5-(2-dimethylamino-ethoxy)-2(4-hydroxy-3,5-dimethylphenyl)-7-methoxy-3Hquinazolin-4-one; 2-(4-hydroxy-3,5-dimethyl-phenyl)-7-methoxy-5-(2-methoxy-ethoxy)-3Hquinazolin-4-one; 7-(2-amino-ethoxy)-2-(4-hydroxy-3, 5-dimethyl-phenyl)-5-methoxy-3Hquinazolin-4-one; 2-(4-hydroxy-3,5-dimethyl-phenyl)-5-methoxy-7-(2-methoxy-ethoxy)-3Hquinazolin-4-one; 7-(2-benzyloxy-ethoxy)-2-(4-hydroxy-3,5-dimethyl-phenyl)-5-methoxy-3Hquinazolin-4-one; 2-(4-hydroxy-3,5-dimethylphenyl)-5-methoxy-7-[2-(pyridin-3-ylmethoxy)ethoxy]-3H-quinazolin-4-one; 7-(2-dimethylamino-ethoxy)-2-(4-hydroxy-3,5-dimethylphenyl)-3H-quinazolin-4-one; 2-(4-hydroxy-3,5-dimethyl-phenyl)-6-(pyridin-4-ylamino)-3H-quinazolin-4-one; 2-(4-hydroxy-3,5-dimethyl-phenyl)-6-(pyridin-2-ylamino)-3H-quinazolin-4-one; 2-(4-hydroxy-3,5-dimethylphenyl)-6-((4-methylpiperazin-1-yl)methyl)quinazolin-4(3H)-one.
Patent NZ-598523-A (NZ)
Title: Method for producing briquettes, method for producing reduced metal, and method for separating zinc or lead
Inventor: MIZUTANI NORIAKI
IPC: C21B13/10
Filed: 2010-09-24
Abstract: Disclosed is a method for producing briquettes, by which briquettes having enhanced strength can be produced even when the amount of a binder used therefor is reduced as much as possible. Specifically disclosed is a method for producing briquettes, which comprises: a step of forming a primary granular material having an apparent density of 1,000 to 4,000 kg/m3 using a powder of metal oxides including iron oxide and one or more oxides selected from among of zinc oxide, lead oxide, and titanium oxide; and a step of forming a secondary granular material by compressing a plurality of primary granular materials, while having the primary granular materials contain one or more metal oxides selected from among the zinc oxide, lead oxide, and titanium oxide; and a step of drying the secondary granular material.
Patent NZ-600535-A (NZ)
Title: Antenna port mapping method and device for demodulation reference signals
Inventor: JONGREN GEORGE
IPC: H04W72/08
Filed: 2010-01-20
Abstract: A method implemented by a base station (12) for transmitting demodulation reference signals to a user terminal and the base station are disclosed. The base station comprises a transmit signal processor (120) and transmit controller(110) and is configured to determine a transmission rank for a downlink transmission to the user terminal and determine one or more reference signal antenna ports for the downlink transmission based on the transmission rank. Each port is defined by a group/code pair comprising a code division multiplexing group and orthogonal cover code. The base station is further configured to map reference signal antenna ports to group/code pairs such that the code division multiplexing group and code orthogonal cover code are the same for a given antenna port for every transmission rank; and transmit the downlink reference symbols over the reference signal antenna ports corresponding to the transmission rank. A method implemented by a user terminal (14) for receiving demodulation reference signals transmitted by a base station and the user terminal are disclosed. The user terminal comprises a receive signal processor (220) and receive controller (210) and is configured to determining a transmission rank for a downlink transmission to the user terminal; determining one or more reference signal antenna ports for the downlink transmission based on the transmission rank. Each port is defined by a group/code pair comprising a code division multiplexing group and orthogonal cover code. The user terminal is further configured to mapping reference signal antenna ports to group/code such that the code division multiplexing group and orthogonal cover code are the same for a given antenna port for every transmission rank; and receiving the downlink reference symbols over the reference signal antenna ports corresponding to the transmission rank.
Patent NZ-601024-A (NZ)
Title: Arylethynyl derivatives
Inventor: VIEIRA ERIC
IPC: A61K31/506
Filed: 2011-04-11
Abstract: Disclosed herein are arylethynyl derivatives of formula (I), wherein the variables shown in formula (I) are as defined in the specification. These arylethynyl derivatives are allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5) and are useful for the treatment of schizophrenia, cognitive diseases, fragile X syndrome or autism.
Patent NZ-601416-A (NZ)
Title: Processes for saccharifying or liquifying a material, e.g., a cellulosic or lignocellulosic feedstock, by converting the cellulosic portion of the material to low molecular weight sugars, e.g., using an enzyme.
Inventor: MEDOFF MARSHALL
IPC: B01F25/64
Filed: 2010-11-18
Abstract: 601416 A method of saccharifying a cellulosic feedstock including the steps of saccharifying a biomass feedstock in a vessel. The biomass feedstock is dispersed in a liquid medium using a dispersing system that draws the feedstock and liquid medium out of the vessel and recirculates the feedstock and liquid medium back into the vessel. The dispersing system includes a chamber and, within the chamber, a rotating member which draws the feedstock and liquid medium into the chamber axially and expels a dispersion of the feedstock in the medium from the chamber radially.
Patent NZ-602089-A (NZ)
Title: Heterocyclic compounds having cell division cycle 7 inhibitory activity
Inventor: HOMMA MISAKI
IPC: A61K31/519
Filed: 2011-02-16
Abstract: The disclosure relates to a pyrazole-substituted thienopyrimidinone derivative which is useful as a prophylactic or therapeutic agent for cancer. Specifically disclosed is a compound represented by formula (I), wherein each symbol is as defined in the specification or a salt thereof, which is useful for the prevention or treatment of cancer. An example of said compound of formula (I) is: 6-(5-Methyl-1H-pyrazol-4-yl)-2-[(2S)-pyrrolidin-2-yl]thieno[3,2-d]pyrimidin-4(3H)-one.
Patent NZ-602705-A (NZ)
Title: Aqueous herbicidal concentrates of auxinic carboxylic acids with reduced eye irritancy
Inventor: TANK HOLGER
IPC: A01N37/44
Filed: 2011-04-19
Abstract: Disclosed herein is a method to reduce the eye irritancy of aqueous herbicidal concentrates of commonly used ammonium salts of auxinic carboxylic acids derived from mono-, di- or trialkylamines, (preferably 2,4-D, triclopyr, aminopyralid, clopyralid, fluroxypyr, picloram or dicamba) which comprises using the N,N,N-trimethylethanolammonium cation as the ammonium salt of the auxinic carboxylic acid. The disclosure particularly relates to the use of an aqueous herbicidal concentrate comprising the N,N,N-trimethylethanolammonium salt of an auxinic carboxylic acid herbicide as an alternative to aqueous herbicidal concentrates that contain one or more salts of auxinic carboxylic acids derived from mono-, di- or trialkylamines, to reduce eye irritancy, wherein the auxinic carboxylic acid IS 2,4-D, triclopyr, aminopyralid, clopyralid, fluroxypyr, picloram or dicamba. Also disclosed is method of improving the solubility in water of auxinic herbicides which comprises using the N,N,N-trimethylethanolammonium cation as the ammonium salt of the auxinic herbicide.
Patent NZ-602808-A (NZ)
Title: Angiogenesis using placental stem cells
Inventor: KAPLUNOVSKY ALEKSANDR
IPC: A61K35/28
Filed: 2011-04-06
Abstract: Disclosed is the use of CD10+, CD34–, CD105+, CD200+ placental stem cells in the manufacture of a medicament for treating an individual having a disease or disorder of the circulatory system, wherein said treating results in a detectable improvement of one or more symptoms of said disease or disorder. Further disclosed is the use of CD10+, CD34–, CD105+, CD200+ placental stem cells in the manufacture of a medicament for treating an individual having a disruption of blood flow in or around a limb, wherein said treating results in a detectable improvement of one or more symptoms caused by said disruption of blood flow.
Patent NZ-610732-A (NZ)
Title: Novel angiotensin type 2 (at2) receptor agonists and uses thereof
Inventor: RINK RICK
IPC: C07K7/14
Filed: 2011-11-22
Abstract: NZ 610732 Disclosed is a cyclic peptide compound consisting of the amino acid sequence Xaa1- Asp- Arg- Ile/Val- Xaa5- Ile/Val- His- Xaa8 comprising a thioether-bridge linkage between the side chains of Xaa5 and Xaa8 such that Xaa5 and Xaa8 together form a structure according to either one of the general formula as disclosed in the specification, wherein R, R1, R2, R3, R4 and R5 are independently selected from –H, a C1- C10 alkyl or aralkyl group, preferably wherein R, R1, R2, R3, R4 and R5 are independently selected from H and CH3, and wherein Xaa1 is selected from the group consisting of charged amino acids, aromatic amino acids and hydrophobic amino acids and D-stereoisomers thereof and pGlu, or a pharmaceutically acceptable salt thereof. Also disclosed is the use of this peptide in the manufacture of a medicament to treat stress and cardiac related disrders.
Patent NZ-611965-A (NZ)
Title: Synthesis and novel salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine
Inventor: AKIREDDY SRINIVISA RAO
IPC: C07D403/06
Filed: 2009-11-30
Abstract: The present disclosure relates to the stereospecific synthesis of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine. Also disclosed are Diethyl (R)-2-(1-(tert-butoxycarbonyl)pyrrolidin-3-yl)malonate, (R)-2-(1-(tert-Butoxycarbonyl) pyrrolidin-3-yl)malonic acid, tert-Butyl (R)-3-(2-hydroxyethyl)pyrrolidine-1-carboxylate, and tert-Butyl (R)-3-(2-iodoethyl)pyrrolidine-1-carboxylate and a method for the synthesis of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine ehre these compoundsare used as intermediates.
Patent NZ-619739-A (NZ)
Title: Corn products and methods for their production
Inventor: PLEHN STEVE J
IPC: A01H1/04
Filed: 2012-07-13
Abstract: Disclosed is inbred corn seed comprising a homozygous brown-midrib-3 (bm3) and a homozygous floury-2 (fl2) genotype. Also disclosed is a method of introducing a brown-midrib trait and floury-endosperm trait into a corn inbred line comprising: (a) crossing recurrent inbred corn plants with donor plants of another corn line that comprise a desired brown-midrib trait and a desired floury-endosperm trait to produce F progeny plants; (b) crossing F 1 progeny plants with the recurrent inbred com plants to produce backcross (BC1) progeny plants, which are then self-pollinated to produce selfed BCI plants; (c) selecting for backcrossed selfed (BC1S1) progeny seeds and plants that respectively comprise the desired floury-endosperm and brown-midrib traits, and physiological and morphological characteristics of the recurrent corn inbred line; and crossing the selected backcrossed selfed (BC1S1) plants with the recurrent inbred com plants to produce the twice-backcrossed selfed (BC2S1) progeny plants, which are then self-pollinated to produce twice backcrossed twice-selfed (BC2S2) plants; (d) performing steps (b) and (c) one or more times in succession to produce the selected or higher backcross progeny plants that comprise the desired brown-midrib trait and floury-endosperm traits and all of the physiological and morphological characteristics of the recurrent com inbred line as determined at the 5% significance level when grown in the same environmental conditions.
Patent NZ-624774-A (NZ)
Title: Process for the synthesis of 3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-triene-7-carbonitrile, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
Inventor: KAMINSKI THOMAS
IPC: C07C255/54
Filed: 2014-05-09
Abstract: Disclosed is a method for the synthesis of 3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-triene-7-carbonitrile (formula I), from the reaction of 3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-triene-7-one (formula VII) with 1-(isocyanomethylsulphonyl)-4-methylbenzene (TosMIC) in the presence of a base in an organic solvent. Also disclosed is a process for the synthesis of the compound of formula VII which is produced by the reaction of 1,2-dibromo-4,5-dimethoxybenzene (formula VIII) with a 1,1-dialkoxyethene and an organometallic in an organic solvent to produce the compound 7,7-dialkoxy-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-triene (formula IX) which is then hydrolysed in an organoaqueous acidic medium to form the compound of formula VII. Also disclosed is a process for the synthesis of ivabradine, wherein the compound of formula VII is converted to the compound of formula I, which is then used to produce ivabradine.
Patent NZ-628284-A (NZ)
Title: Antibodies specific for claudin 6 (cldn6)
Inventor: WALTER KORDEN
IPC: C07K16/28
Filed: 2010-11-11
Abstract: Disclosed is an antibody which binds to an epitope located within an extracellular portion of CLDN6 associated with the surface of a cell that expresses CLDN6 and which does not detectably bind to CLDN9 associated with the surface of a cell that expresses CLDN9. Also disclosed is an antibody which binds to CLDN6, wherein the antibody comprises an antibody heavy chain comprising the CDR3 sequence Xaa1 Gly Xaa2 Val Xaa3, wherein Xaa1, Xaa2 and Xaa3 is any amino acid, wherein the antibody does not detectably bind to CLDN9 associated with the surface of a cell that expresses CLDN9. Further disclosed is the use of said antibody in the manufacture of a medicament for treating cancer.
Patent NZ-630549-A (NZ)
Title: N-ethyl-4-hydroxyl-1-methyl-5- (methyl(2,3,4,5,6-pentahydroxyhexyl) amino) -2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide
Inventor: LAXER AVITAL
IPC: A61K31/4704
Filed: 2013-05-07
Abstract: N-ETHYL-4-HYDROXYL-1-METHYL-5- (METHYL(2,3,4,5,6-PENTAHYDROXYHEXYL) AMINO) -2-OXO-N-PHENYL-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDE
Patent NZ-713669-A (NZ)
Title: Methods of altering eddy current interactions
Inventor: DIEHL ANDREW KARL
IPC: F16D63/00
Filed: 2014-12-04
Abstract: A braking mechanism comprising:at least one magnetic field provided by magnetic elements, the magnetic elements including one north polarity facing magnet element and one south polarity facing magnet element aligned; at least one additional magnet in the form of magnetic cladding about the north and south polarity facing magnet elements, the magnetic cladding acting to modify a magnetic flux density about the predetermined region between the north polarity facing magnet element and the south polarity facing magnet element; and at least one conductive member or a part thereof; wherein, when the at least one conductive member or part thereof does not interact with the predetermined region, independent movement occurs between the conductive member and the predetermined region, and, when the at least one conductive member or part thereof interacts with the predetermined region, eddy current drag forces are generated resisting relative movement and urging dependent movement between the at least one conductive member or part thereof and the predetermined region.
Patent NZ-718371-A (NZ)
Title: Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
Inventor: GOSSELIN MICHAEL
IPC: A61K9/20
Filed: 2014-09-05
Abstract: The present invention is directed to orally administered compositions of topically acting corticosteroids for the treatment of inflammation of the gastrointestinal tracts such as eosinophilic esophagitis. The present invention also provides a method for treating conditions associated with inflammation of the gastrointestinal tract in an individual The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention as orally disintegrating tablets comprising a topically active corticosteroid adsorbed onto a pharmaceutically acceptable carrier such as silicified microcrystalline cellulose.
Patent NZ-735659-A (NZ)
Title: Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack
Inventor: SEXTON DANIEL
IPC: C07K16/40
Filed: 2016-03-30
Abstract: Provided herein are plasma kallikrein antibodies binding to active plasma kallikrein and methods of using such antibodies in preventing hereditary angioedema attack or reducing the rate of hereditary angioedema attack. A specific embodiment includes the use of the antibody DX-2930 in the manufacture of a medicament for preventing hereditary angioedema (HAE) attack or reducing the rate of HAE attack in a subject, wherein the antibody comprises a heavy chain CDRs 1-3 defined by SEQ ID Nos 5-7 and light chain CDRs defined by SEQ ID Nos 8-10 wherein the antibody is formulated in a pharmaceutically acceptable carrier wherein the medicament is to be administered at about 300 mg of the antibody every two to four weeks at least two times, and wherein the subject is a patient experiencing at least two HAE attacks per year prior to the administration.
Patent NZ-741906-A (NZ)
Title: Water pipe with synchronously retractable multi-layer
Inventor: SONGLIN DAI
IPC: F16L11/20
Filed: 2018-04-24
Abstract: Disclosed is A water pipe with synchronously retractable multi-layer, comprising: a retractable inner pipe; a fabric sleeve sleeved outside the inner pipe, which is configured as a retractable cylindrical or corrugated one- or multi-layer fabric sleeve formed by interweaving retractable elastic yarns arranged at intervals in the axial direction and non-retractable reinforcing yarns arranged at intervals in the circumferential direction; and a retractable plastic film layer interposed between the inner pipe and the fabric sleeve. According to the present disclosure, the inner pipe, the plastic film layer and the fabric sleeve can be synchronously retracted under the effect of water pressure change, so that the frictional damage among multiple layers is effectively reduced, and the service life of the entire retractable water pipe is prolonged.
Patent NZ-746116-A (NZ)
Title: Heat compensating roofing boards
Inventor: BUHRMAN CHAD
IPC: E04D11/02
Filed: 2017-03-10
Abstract: A roofing board, such as a polyiso insulation board (10), includes first and second surfaces (11, 12), where the first surface (11 ) is lighter in color than the second surface (12). This allows the roofing installer to choose which of the surfaces (11, 12) to expose to the atmosphere, the lighter surface (11 ) being cooler than the darker surface (12). The lighter surface (11 ) may have a solar reflectance greater than the darker surface (12). A roofing membrane (14) is then adhered or otherwise attached to the exposed surface. The first surface also has a greater tack free time when adhesive is used on it than the second surface.
Patent NZ-754996-A (NZ)
Title: Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
Inventor: MOUSSA ADEL
IPC: C07F9/6521
Filed: 2018-01-31
Abstract: A hemi-sulfate salt of the structure as depicted in the drawing below, to treat a host infected with hepatitis C, as well as pharmaceutical compositions and dosage forms, including solid dosage forms, thereof.
Patent NZ-767816-A (NZ)
Title: Nasal assembly
Inventor: JUDSON DANIEL ROBERT
IPC: A61M16/06
Filed: 2006-10-13
Abstract: A mask assembly for delivering pressurized gas to a patient for treatment of sleep disordered breathing, the mask assembly comprising: a cushion configured to seal with the patient’s face to deliver the pressurized gas to at least the patient’s nares; a frame configured to retain the cushion, the frame and the cushion together at least partially forming a breathing chamber, the frame including an aperture configured to receive the pressurized gas into the chamber, a first axis extending through a center of the aperture; an air delivery tube to deliver the pressurized gas to the chamber; a fluid connector configured to be connected to the frame at the aperture, the fluid connector forming a gas passageway for conveying the pressurized gas from the air delivery tube to the chamber, the first axis extending along the gas passageway; and a vent configured to provide washout from the breathing chamber of gas exhaled by the patient, the vent comprising 5-50 holes forming an arc shape that extends at least half way around the first axis when the fluid connector is connected to the frame, wherein each of the plurality of vent holes includes an outlet exposed to ambient pressure.
Patent NZ-785500-A (NZ)
Title: Depth sensing systems and methods
Inventor: LINK GREGORY
IPC: G01B11/22
Filed: 2017-02-28
Abstract: Disclosed is a depth sensing system, comprising a spatially modulated light projection device to project light toward a surface, and a sensor to receive the light reflected from the surface. An actuator controls spatial modulation of the light projection device to form first and second sin waves that are phase-offset from each other to form a plurality of intersecting light segments. A processor receives light information from the sensor and to analyze the light reflected from the surface to determine a depth of the surface. The light comprises infrared light having a wavelength from about 700 nm to about 1 mm. The actuator controls spatial modulation of the light projection device to sequentially change a subset of the plurality of the intersecting light segments to form a dynamic pattern.
Patent PT-100227-A (PT)
Inventor: BUCHMANN BERND
IPC: C07C235/40
Filed: 1992-03-11
Abstract: The invention discloses new leukotriene B4 derivatives of formula (I), wherein R?1 stands for CH2?OH, CH3?, CF3?, COOR?5, CONR?6R?7, or R?1 together with R?2 stands for a carbonyl group, R?2 and R?3 are the same or different and stand for H or an organic acid residue containing 1 to 15 carbon atoms, R?4 stands for H, C1?-C10? alkyl, possibly substituted one or more times by chlorine or bromine, C3?-C10? cycloalkyl, a C6?-C10? aryl residue possibly substituted one or more times by chlorine, bromine or phenyl, C1?-C4? alkyl, C1?-C4? alkoxy, fluoromethyl, chloromethyl, trifluoromethyl, carboxy or hydroxy, or a 5- or 6-membered aromatic heterocyclic ring with at least one heteroatom, R?5 stands for hydrogen, C1?-C10? alkyl, C3?-C10? cycloalkyl, a C6?-C10? aryl residue possibly substituted one to three times by chlorine, bromine or phenyl, C1?-C4? alkyl, C1?-C4? alkoxy, fluoromethyl, chloromethyl, trifluoromethyl, carboxy or hydroxy, CH2?-CO-(C6?-C10?) aryl or a 5- or 6-membered ring with at least one heteroatom, A stands for a trans,trans-CH=CH-CH=CH, a -CH2?CH2?-CH=CH- or a tetramethylene group, B stands for a C1?-C10? straight-chain or branched-chain alkylene group, possibly substituted by fluorine, or the group of formula (a), D stands for a direct bond, oxygen, sulphur, -C=C-, -CH=CR8? or, together with B, for a direct bond, R6? and R7? are the same or different and stand for H or C1?-C4? alkyl or R7? stands for H and R6? stands for C1?-C10? alkanoyl or C1?-C10? alkanesulphonyl, R8? stands for H, C1?-C5? alkyl, chlorine or bromine, n is equal to 3 to 5 and, when R5? stands for hydrogen, their salts with physiologically tolerable bases and their cyclodextrin clathrates.